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systemic disease characterized by the association of myositis, interstitial
lung disease, polyarthralgia, and/or polyarthritis, has not yet been
evaluated with regard to phenotype, prognosis, and response to treat-
ment. ACPA-positive ASS patients were first identified among a French
multicenter registry of patients with ASS. Additionally, all French
rheumatology and internal medicine practitioners registered on the
Club Rhumatismes et Inflammation web site were asked to report their
observations of ASS patients with ACPA. The 17 collected patients
were retrospectively studied using a standardized questionnaire and
compared with 34 unselected ACPA-negative ASS patients in a case–
control study. All ACPA-positive ASS patients suffered from arthritis
versus 41% in the control group (P< 0.0001). The number of swollen
joints was significantly higher (7.0 5.0 vs 2.9 3.9, P< 0.005), with a
distribution resembling that of RA. Radiographic damages were also
more frequent in ACPA-positive ASS patients (87% vs 11%,
P< 0.0001). Aside from a significantly higher transfer factor for carbon
monoxide in ACPA–ASS patients, lung, muscle, and skin involvements
had similar incidences, patterns, and severity in both groups. Although
Nonbiologic treatments were similarly used in both groups, ACPA-
positive patients received biologics more frequently (59% vs 12%,
P< 0.0008), mostly due to refractory arthritis (n¼ 9). Eight patients
received anti-Cluster of differentiation 20 (CD20) monoclonal anti-
bodies (mAbs) with good efficacy and tolerance, whereas 2 of the 5
patients treated with antitumor necrosis factor drugs had worsened
myositis and/or interstitial lung disease. After a >7-year mean fol-
low-up, extra-articular outcomes and survival were not different.
ACPA-positive ASS patients showed an overlapping RA–ASS syn-
drome, were at high risk of refractory erosive arthritis, and might
experience ASS flare when treated with antitumor necrosis factor drugs.
In contrast, other biologics such as anti-CD20 mAb were effective in
this context, without worsening systemic involvements.
(Medicine 94(20):e523)
Abbreviations: ACPA = anticitrullinated peptide/protein
antibodies, Anti-ARS = antiaminoacyl-transfer RNA synthetase,
ASS = antisynthetase syndrome, CK = creatine kinase, DLCO =
diffusing capacity of the lung for carbon monoxide, DM =
dermatomyositis, FVC = forced vital capacity, HRCT = high-
resolution computed tomography, ILD = interstitial lung disease,
IPJ = interphalangeal joint, MMT = manual muscle testing, OR =odds ratio, mAb = monoclonal antibody, RA = rheumatoid arthritis,
SE = shared epitope, SJC = swollen joint count, TJC = tender joint
count, ULN = upper limit of normal.
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N umerous studies have confirmed that anticitrullinated pep-tide/protein antibodies (ACPAs) are both highly sensitive
and specific for rheumatoid arthritis (RA).1 This has recently led
to their inclusion in the serological criteria for the classification
of RA.2 In this disease, ACPAs also have a high prognostic
significance as they are associated with higher disease activity,3
radiographic progression,4 and poorer response to therapy.5
However, despite their high specificity, ACPA may be
found in some patients with other systemic autoimmune dis-
eases, including systemic sclerosis6–8 and systemic lupus.9–12
Importantly, in these settings, ACPA positivity has been linked
to bone erosions resembling RA. For example, in systemic
lupus, ACPA positivity is associated with ‘‘rhupus’’ in which
the signs and symptoms of RA prevail.13,14
The occurrence of ACPA in antisynthetase syndrome
(ASS) has been documented in only a few case reports15–21
or series involving <10 patients.22 ASS is also a systemic
autoimmune connective tissue disease, characterized by the
association of interstitial lung disease (ILD), inflammatory
myopathy, Raynaud phenomenon, and/or mechanic’s hands
with the presence of antiaminoacyl-transfer RNA synthetase
(anti-ARS) antibodies. Arthritis and/or arthralgia are present in
up to 90% of these patients,23–25 and joint disease is the initial
symptom in 21% to 32% of patients with ASS.19,21 Subluxation
arthropathy has been described in 19% of anti-Jo1–ASS
patients,26,27 whereas joint damages are less common, ranging
generally from 0% to 8%.26–29
In light of the above, we retrospectively studied cases of
patients displaying ACPA in the context of ASS with the aim of
assessing the clinical significance of this association with regard
to phenotype, prognosis, and response to treatment.
METHODS
Patients
In this case–control retrospective study, patients with
ACPA (n¼ 7) were first identified among a French 9-center
registry of 284 patients with ASS.25
Additionally, all French rheumatology and internal medi-
cine practitioners registered on the Club Rhumatismes et Inflam-
mation web site (representing>1400 physicians) were contacted
by 2 successive electronic newsletters and asked to report their
observations of ASS patients with ACPAwho met the following
inclusion criteria: 2 successive positive tests for anti-ARS,
including LUMINEX-100 system (Luminex, Austin, TX),
ENA-LISA-kit (BioMedical Diagnostics, Marne-la-Valle´e,
France), or IMMUNO-DOT (Euroimmun AG, Lu¨beck,
Germany; DiaSorin, Saluggia, Italy); clinical involvement in
accordance with ASS, including pulmonary, muscle, dermatolo-
gical, or rheumatic involvements;23 ACPA positivity using anti-
cyclic citrullinated peptide 2 (CCP2) assays, including BioPlex
2200 System (Bio-Rad Laboratories, Hercules, CA), Immunos-
can-CCP Plus (Eurodiagnostica, the Netherlands, Arnhem),
Quantalite CCP2 (Inova, San Diego, CA), and Elecsys anti-
CCP (Roche, Meylan, France). Among 13 reported patients,
3 did not meet the inclusion criteria: 2 patients had solely
rheumatic involvement and 1 had solely pulmonary involvement.
Patients were included from May 1, 2012 to May 1, 2014.
The 17 ACPA-positive ASS patients included in the study
were compared with 34 unselected ASS patients from the French
9-center registry matched for age, sex, and follow-up, fulfilling
inclusion criteria,1,2 whereas being tested negative for ACPA.
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Demographic information, comorbidities, clinical history
of ASS, imaging findings (including hand and foot radiographs,
high-resolution computed tomography (HRCT)] thoracic scans,
pulmonary function tests, biological data, and detailed medical
treatment were collected. Data collection was compiled by
A.M., G.L., and B.H. using the same standardized form.
Definitions
ACPAwere considered positive when superior to the upper
limit of normal (ULN) for the laboratory of immunology.2
Joint involvement included arthralgia and/or arthritis.
Severity was assessed through higher recorded values of tender
joint count (TJC), swollen joint count (SJC), and appearance of
radiographic damage. Radiographic damage was defined by the
presence of bone erosion and/or joint narrowing on standard
radiographs of the hand and/or the foot. All radiographs were
examined by experienced radiologists and rheumatologists.
Hand radiographs were also retrospectively examined blinded
to ACPA status by A.M., G.B., and J.S., and radiographic
damages were scored using the Sharp method30 with additional
scoring of the distal interphalangeal joints (IPJs) of the hands.
Consensus was always obtained.
Pulmonary involvement was defined by the presence of an
ILD on HRCT, confirmed in most cases by abnormal pulmonary
function tests (forced vital capacity [FVC]< 70% and/or diffus-
ing capacity of the lung for carbon monoxide [DLCO]< 70%).
Muscle involvement31 was defined either by the occurrence
of myalgia, muscle weakness (Medical Research Council 5 sum
score 4 for at least 1 muscle group evaluated by manual
muscle testing [MMT]), along with increased creatine kinase
(CK) level >2 times the normal level, myopathic changes on
electromyography, or typical features in muscle biopsies
(assessed by different pathologists experienced in muscle histo-
pathology).
Outcome was assessed for each patient during the follow-
up period. Changes 30% in TJC and/or SJC were considered
to be significant in defining aggravation, stability, and improve-
ment of joint disease. Pulmonary aggravation, stability, and
improvement were defined as changes in pulmonary function
tests >15% for DLCO or >10% for FVC, in accordance with
the international consensus statement of the American Thoracic
Society on idiopathic pulmonary fibrosis,26 concordant with
evolution in dyspnea according to New York Heart Association
stages, and/or to HRCT results. Muscle aggravation, stability,
and improvement, respectively, corresponded to a decrease,
stability, or increase in MMT or a 2-fold modification in
CK levels, as compared with the time of ASS diagnosis.
Statistical Analysis
Quantitative data were described as mean SD (unless
specified otherwise). Mann–Whitney and Fisher tests were used
for comparison of continuous and categorical variables, respect-
ively. The Kaplan–Meyer method and log rank tests were used
to compare survival between groups. Only a P value <0.05 was
considered significant. All analyses were performed using
GraphPad Prism 5 software (San Diego, CA).
RESULTS
Medicine  Volume 94, Number 20, May 2015Polyarthralgia and/or polyarthritis were the first symptoms
to appear in the majority of ACPA-positive ASS patients
(n¼ 88%), whereas myositis and/or ILD were present at onset
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Comparison of Clinical Manifestations Between ACPA-Positive and ACPA-Negative SAS Patients
ACPA () N¼ 34 ACPA (þ) N¼ 17 OR (95% CI) P
Age at onset, y (range) 45.6 15.4 42.1 10.8 — 0.44
Male 4 (12%) 4 (24%) 0.43 (0.093–2.00) 0.42
Anti-Jo-1 25 (74%) 12 (71%) 0.86 (0.23–3.14) 1.00
Anti-PL-12 7 (21%) 2 (12%) 0.51 (0.095–2.80) 0.70
Anti-PL-7 2 (6%) 3 (18%) 3.43 (0.52–22.85 0.32
Joint involvement (arthralgia
and/or arthritis)
29 (85%) 17 (100%) 6.53 (0.34–125) 0.16
Arthritis 14 (41%) 17 (100%) 49.48 (2.75–891) <0.0001
TJC

11.3 7.7 13.2 1.7 — 0.35
SJC

2.9W 3.9 7.0W 5.0 — 0.0022
Articular damage on
standard hand and/or
foot radiographs

3 of 27 (11%) 13 of 16 (87%) 34.67 (6.10–197) <0.0001
Sharp score (including
DIP scoring)
 5.8W 3.2 in 14 patients with JD 35.3W 21.6 in 9 patients with JD — 0.029
Lung involvement 28 (82%) 14 (82%) 1.00 (0.22–4.61) 1.00
NYHA> 2y 6 (21%) 2 (14%) 0.61 (0.11–3.51) 0.70
FCVy 68.11 22.37 79.50 20.67 — 0.068
DLCOy 50.78W 21.92 69.58W 18.73 — 0.046
NSIPy 22 (78.5%) 9 (64%) 0.49 (0.12–2.03) 0.46
UIPy 5 (18%) 4 (29%) 1.84 (0.41–8.33) 0.45
OPy 1 (3.5%) 1 (7) 2.08 (0.12–35.9) 1.00
Muscle involvement 27 (79%) 14 (82%) 1.21 (0.27–5.42) 1.00
Muscle weaknessz 16 (59%) 11 (79%) 2.52 (0.57– 11.19) 0.31
Serum CK levelz 3540 7355 3124 3382 — 0.67
Myopathic changes
on EMGz
16 (84%) of 19 patients with myositis 6 (75%) of 8 patients with myositis 0.56 (0.075–4.24) 0.62
Inflammatory infiltrate
and/or fiber necrosis
on muscle biopsyz
16 (80%) of 20 patients with myositis 7 (100%) of 7 patients with myositis 0.25 (0.055–1.14) 0.14
Skin involvement 14 (41%) 7 (44%) 1.00 (0.31–3.27) 1.00
Mechanic’s hand 9 (26%) 2 (12%) 0.37 (0.070– 1.95) 0.30
Sclerodactyly 7 (21%) 1 (6%) 0.19 (0.021– 1.68) 0.13
DM rash 2 (6%) 4 (24%) 4.92 (0.80–30.27) 0.09
Raynaud phenomenon 19 (56%) 8 (47%) 0.70 (0.22–2.26) 0.57
CRP amount, mg/dL 2.80W 4.36 5.32W 5.37 — 0.007
Rheumatoid factor 5 (15%) of 33 patients 14 (88%) of 16 patients 39.20 (6.74–228) <0.0001
HLA-SE 2 (25%) of 8 patients 5 (50%) of 10 patients 3.00 (0.40–22.72) 0.37
Tobacco use (ever) 5 (15%) 5 (29%) 2.9 (0.69–12.16) 0.25
Corticosteroids 24 (100%) 17 (100%) — NS
Methotrexate 17 (50%) 13 (76%) 3.25 (0.88–12.01) 0.082
Plaquenil 5 (15%) 5 (29%) 2.42 (0.59–9.90) 0.27
Leflunomide 2 (6%) 5 (29%) 6.67 (1.14–39.12) 0.034
Azathioprine 9 (26%) 2 (12%) 0.37 (0.070–1.95) 0.30
Mycophenolate mofetil 10 (29%) 2 (12%) 0.32 (0.062–1.67 0.29
Cyclophosphamide 8 (24%) 4 (24%) 1.00 (0.25–3.95) 1.00
IV-Ig 7 (21%) 1 (6%) 0.24 (0.027–2.14) 0.24
Biologics 4 (12%) 10 (59%) 10.71 (2.58–44.42) 0.0008
Biologics due to JD
refractory to DMARDs
 1 (3%) 9 (53%) 47.14 (5.16–431) <0.0001
Follow-up, mo 96.18 77.53 93.19 61.31 — 0.80
Death 6 (18%) 0 (0%) 0.13 (0.0070–2.51) 0.26
Presented values are the worst values during the entire follow-up. ACPA¼ anticitrullinated peptide/protein antibody, CK¼ creatine kinase,
CI¼ confidence interval, CRP¼C-reactive protein, DIP¼ distal-interphalangeal, DLCO¼ diffusing capacity of the lung for carbon monoxide,
DM¼ dermatomyositis, DMARD¼ disease-modifying antirheumatic drug, EMG¼ electromyogram, FCV¼ forced vital capacity, HLA¼human
leukocyte antigen, IV-Ig¼ intravenous immunoglobulin, NSIP¼nonspecific interstitial pneumonia, NYHA¼New York Heart Association,
OP¼ organizing pneumonia, OR¼ odds ratio, SE¼ shared epitope, SJC¼ swollen joint count, TJC¼ tender joint count, UIP¼ usual interstitial
pneumonia.
In patients with joint involvement.
y In patients with lung involvement.
Medicine  Volume 94, Number 20, May 2015 ACPA in ASS Are Associated With Severe and Erosive Arthritisin 41% and 35% of patients, respectively. ACPA were ident-
z In patients with muscle involvement.ified 3 months (range 0–132) after the first symptoms whereas
antisynthetase autoantibodies were found 2 months (range
0–145) after disease onset. Initial diagnoses were RA
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.(n¼ 6), ASS (n¼ 5), dermatomyositis (DM) (n¼ 3), polymyo-
sitis (n¼ 1), and RA–ASS overlapping syndrome (n¼ 2).
Clinical characteristics of the 17 ACPA–ASS patients are
shown in Table 1.
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tive difference in nonbiologic treatments received between both
groups. Biologics, including rituximab (n¼ 8), infliximab
(n¼ 4), etanercept (n¼ 1), adalimumab (n¼ 1), tocilizumabDemographic Characteristics
Among the 17 ACPA-positive ASS patients, there were
4 men and 13 women, with a mean age at onset of 45.6 15.4
years (Table 1). There were no significant differences in terms
of sex or age at onset between ACPA-positive ASS patients and
the control group. Of note, the proportion of smokers was not
significantly higher in ACPA-positive ASS patients (29% vs
15%, P¼ 0.25).
Clinical Characteristic of ACPA-Positive ASS
Patients
Despite a similar incidence of joint involvement in both
groups, all ACPA-positive ASS patients suffered from arthritis
versus 14 patients (41%) in ACPA-negative ASS patients, result-
ing in an odds ratio (OR) for arthritis of 49.5, 95% confidence
interval (CI) 2.8–891, and P< 0.0001 (Table 1). When solely
considering patients with joint involvement, the number of
swollen joints was significantly higher in the ACPA-positive
ASS group (2.9 3.9 vs 7.0 5.0, P¼ 0.0022). Distribution of
arthritis (n¼ 16/17) was always symmetric and mainly involved
metacarpophalangeal (MCP) joints (n¼ 14), wrists (n¼ 10), and
proximal IPJ of both hands (n¼ 8). Knees (n¼ 7), ankles (n¼ 4),
elbows (n¼ 4), and distal IPJ (n¼ 1) were less commonly
involved. There was no difference in the pattern of joint involve-
ment between ACPA-positive and ACPA-negative patients.
Although ILD affected 82% of the patients in both groups,
ASS patients with ACPA tended to display higher FVC
(68.11 22.37 vs 79.50 20.67) and had higher DLCO com-
pared with the ACPA-negative group (50.78 21.98 vs
69.58 18.73, P¼ 0.046). The distribution of the different
ILD patterns, according to international consensus,32 was similar
in both groups. No patient exhibited pulmonary rheumatoid
nodules.
Patients from both groups were equally affected by myo-
sitis (about 80%, P¼ 1.00). Furthermore, there were no differ-
ences with regard to occurrence of muscle weakness (59% vs
79%, P¼ 0.31), CK amount (3540 7355 vs 3124 3382,
P¼ 0.67), and frequency of myopathic changes recorded on
electromyogram (84% vs 75%, P¼ 0.62). When performed
(n¼ 7), muscle biopsy features in patients with ACPA included
inflammatory infiltrate (endomysial n¼ 3, perimysial n¼ 2,
and perivascular n¼ 2), muscle fiber necrosis (n¼ 4), and
perifascicular atrophy (n¼ 2), which did not differ from the
ACPA-negative group (data not shown).
Patients with ACPA also exhibited Raynaud phenomenon
(47%), DM rash (24%), mechanic’s hands (12%), and/or scler-
odactyly (6%), in similar proportions to the control ASS group.
Radiographic Characteristics of ACPA-Positive
ASS Patients
Radiographic damages were more frequent in ACPA–ASS
patients (13/16 [87%]) vs 3/27 (11%) patients with joint disease
(OR 34.67, 95% CI 6.1–197.0, P< 0.0001) (Table 1 and
Figure 1). In ACPA–ASS patients, bone erosion and/or joint
narrowing were observed 40.8 19.8 months after joint disease
onset, and involved MCP joints (n¼ 9), metatarsophalangeal
joints (n¼ 7), wrist (n¼ 4), PIP (proximal interphalangeal)
joints (n¼ 4), and/or DIP (distal interphalangeal) (n¼ 1). In
contrast, in the 3 ACPA-negative patients with radiographic
damages, only joint narrowing with no erosion was observed,
Meyer et alinvolving wrists (n¼ 3), MCP (n¼ 2), PIP (n¼ 1), and/or DIP
(n¼ 1) joints, all of which tended to be diagnosed later during
follow-up: median 63 months, range 106–118 (P¼ 0.11).
4 | www.md-journal.comSharp score (including DIP joints) assessed blindly the
ACPA status after examination of the last available hand
radiographs, and was higher in ACPA-positive patients
(n¼ 9/17, 53%) compared with ACPA-negative patients
(n¼ 14/34, 41%): 35.3 21.6 vs 5.8 3.2, P< 0.05.
Biological Characteristics
Distribution of anti-ARS specificities was similar between
the 2 groups, anti-Jo1 being the most common (always above
70% of patients, Table 1). Median ACPA-titer in ACPA–ASS
patients was 200UI/L, range 33–7742. Rheumatoid factor was
found in 14/16 patients (88%) versus 5/33 patients (15%) in the
control group (OR 39.20, 95% CI 6.74–228, P< 0.0001), and
ACPA-positive ASS patients exhibited higher CRP amount
compared with ACPA-negative ASS patients (5.32mg/
dL 5.37 vs 2.80 4.36, P¼ 0.007). Among 10 ASS patients
with ACPA tested for human leukocyte antigen (HLA) haplo-
types, 5 (50%) were HLA-shared epitope (SE) positive (HLA-
DR4 [n¼ 4] or HLA-DR10 [n¼ 1], heterozygous in all cases),
although this occurrence was similar to the ACPA-negative
group (25%, P¼ 0.37).
Treatments
Mean follow-up after onset of symptoms was 96.2 77.5
and 93.2 61.3 months in ACPA-negative and ACPA-positive
groups, respectively (P¼ 0.80) (Table 1).
All of the patients with ACPA received prednisone (n¼ 17)
with a maximum dosage during follow-up (46.8 17.8mg/d)
comparatively with the ACPA-negative patients (42.2
19.5mg/d (n¼ 25), P¼ 0.35). Additionally, at least 1 additional
immunomodulating therapy was used, including methotrexate
(n¼ 13), hydroxychloroquine (n¼ 5), leflunomide (n¼ 5), sul-
fasalazine (n¼ 2), azathioprine (n¼ 2), mycophenolate mofetil
(n¼ 2), cyclophosphamide (n¼ 4), and/or intravenous immuno-
globulin (n¼ 1). At the end of the follow-up period, at least 2
nonbiologic drugs were used in both groups (P¼ 0.53). With the
exception of leflunomide, which was more frequently given in
ACPA-positive ASS patients (P¼ 0.007), there was no qualita-
Medicine  Volume 94, Number 20, May 2015FIGURE 1. Representative hand radiographs in ASS patients with
ACPA. ACPA¼ anticitrullinated peptide/protein antibody, ASS¼
antisynthetase syndrome.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Medicine  Volume 94, Number 20, May 2015(n¼ 1), and/or abatacept (n¼ 1), were more frequently used in
ACPA-positive patients (59%vs 12%,P< 0.0008). Of note, in 9/
10 ACPA–ASSpatients treated with biologics, the indication for
initiatingsuch treatment was refractory arthritis.
Biologics Tolerance and Efficacy
In 10 patients, a total of 16 biologic courses were used that
included anti-Cluster of differentiation 20 (CD20) monoclonal
antibody (mAb) (n¼ 8), antitumor necrosis factor (TNF) drugs
(n¼ 6 courses in 5 patients, 1 patient receiving infliximab
followed by adalimumab), anti-interleukin-6 receptor mAb
(n¼ 1), and inhibitor of T-cell costimulation (n¼ 1) (Table 2).
Anti-CD20 mAb led to joint efficacy along with improve-
ment and/or stability of extra-articular involvements in all cases
(n¼ 8).
Anti-TNF treatments resulted in joint improvement in 4/6
courses (67%). However, in 2 cases (33%), systemic involve-
ment worsened (myositis n¼ 2 and/or ILD n¼ 1).
In patients treated with other biologics (n¼ 2), both experi-
enced improvement in joint disease, without systemic flare-up of
ASS, although they exhibited increases in transaminase levels (up
to 10-fold that of ULN, whereas CK amount was normal) and
severe bronchopulmonary infection, leading to drug withdrawal.
Outcomes
At the last clinical evaluation, joint disease had improved in
themajority of patients in both groups (23/25 and 16/17,P¼ 1.0).
In the ACPA-negative group, 6 of the 23 patients with lung
disease had worsened ILD versus 1 in the ACPA–ASS patients
(P¼ 0.27). Myositis had improved in all cases, regardless of
ACPA status. Seven ACPA-positive patients (41%) were still
under corticosteroid treatment with a dosage10mg/d versus 8/
27 (30%) in the ACPA-negative group (P¼ 0.53). Finally, all
patients withACPAwere alive at the end of the follow-up period,
whereas 4 patients in the control group had died (P¼ 0.29).
Causes of death were ILD (n¼ 3) or concomitant multiple
myeloma (n¼ 1).As a result, the survival ratewasnot statistically
different between the 2 groups (P¼ 0.15, Figure 2).
DISCUSSION
This study, which is the first case–control study to assess
the clinical significance of ACPA in patients with ASS, suggests
that ASS-patients with ACPA have an overlapping RA–ASS
syndrome. Indeed, polyarthritis was present in all ACPA-
positive patients, involving numerous small joints, with a
distribution resembling that of RA, along with higher CRP
amount and a positive test for rheumatoid factor. Thus, although
all patients displayed ASS manifestations and were tested
positive for ARS at least twice, all ACPA-positive patients
also fulfilled the recently proposed 2010 American College of
Rheumatology diagnostic criteria for RA2 versus 19 ACPA-
negative patients (P¼ 0.0008). Accordingly, and as also
demonstrated in the setting of RA, ACPA positivity in ASS
patients was associated with a greater occurrence of disease-
modifying antirheumatic drugs (DMARDs)-refractory arthritis
as well as a higher incidence of joint damages.
Arthritis, ILD, and Raynaud phenomenon are symptoms
encountered in both RA and ASS.24,25,33,34 Thus, one third of
our ACPA–ASS patients were first diagnosed as having solely
Meyer et alRA. However, during the course of the follow-up, all but 2
patients developed at least 1 additional sign of ASS, including
typical dermatological signs and/or myositis. Finally, the
6 | www.md-journal.comoccurrence of lung, muscle, and skin involvement did not differ
between ACPA-positive and ACPA-negative patients. This
suggests that RA patients experiencing such systemic symptoms
should be tested for anti-ARS as these autoantibodies are
associated with ASS even in the setting of RA. A higher DLCO
was recorded in ACPA–ASS patients with ILD, which was the
only difference in extra-articular involvement between the 2
groups. DLCO has been shown to be a predictor of survival time
in ILD patients32 including RA–ILD35 and myositis–ILD.36
Although 4 deaths were recorded in the ACPA-negative group
versus none in the ACPA-positive group, difference in survival
between the 2 groups did not reach statistical significance
despite prolonged follow-up.
ACPA is strongly associated with the HLA-DRB1 SE and
with smoking.ACPA–ASSpatients tended to bemore frequently
smokers and HLA-SE positive. However, as the trend did not
reach statistical significance (likely due to the limited number of
patients herein), the role of these factors in the development of
ACPA during ASS remains to be further explored.
The present data extend the findings of the 9 previously
describedACPA–ASSpatients, reported as separate case reports,
in which the presence of ACPA was systematically associated
with erosive arthritis15–20,37 (Table 3). This is also in keeping
with recent findings from Kaneko et al,22 which reported that in
ASS patients with available hand X-rays, erosions were associ-
ated with higher rates of positive ACPA and rheumatoid factors.
Among 90 consecutive patients with idiopathic inflammatory
myopathy, the 12 patients that were tested positive for ACPA
(including only 2 patients with anti-ARS) did not show any
clinical or biological differences compared with ACPA-negative
patients, except for rheumatoid factor positivity.21 This discre-
pancy with the present findings may be the result of the small
number of ACPA–ASS patients, differences in diagnostic test
specificity,38 and/or limited follow-up.
According to the present data and given that structural
damages in RA are believed to be largely irreversible albeit
preventable by tight control of joint disease, we suggest that
ACPA should be searched in ASS patients, especially those with
severe polyarthritis and high CRP amount.
In the current series, the ACPA-positive patients experi-
FIGURE 2. Kaplan–Meyer survival curve (from disease onset)
comparing patients with (n¼17) and without (n¼34) ACPA.
ACPA¼ anticitrullinated peptide/protein antibody.enced more frequently DMARDs refractory. Although there is
no consensual therapeutic strategy for such patients in ASS, in
RA patients, it is recommended to start biologic DMARDs, and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.current practice would be to start a TNF inhibitor.39 However, it
has recently been reported that anti-TNF agents may not be
effective in ASS patients and may even trigger myositis and/or
ILD in ASS.17,18 Indeed, among 6 anti-TNF courses in our
series, 1 led to the development of myositis and ILD, whereas
another led to worsening myositis. Because Rituximab has
demonstrated efficacy in RA40 and might be effective in
ASS muscle, lung, and joint disease,41–44 this drug has fre-
quently been given. No serious adverse event was observed and
arthritis improved in all cases along with stability and improve-
ment of extra-articular manifestations, suggesting that this
biologic is safe and efficient in ACPA–ASS patients with
severe refractory joint diseases.
This study assessed the clinical significance of ACPA
retrospectively in a real-life management of ASS patients.
ACPA were not tested in all the patients recorded in the
multicenter registry, and it is possible that a proportion of
ASS patients included in this study were tested for ACPA
because they had polyarthralgia and/or polyarthritis. Indeed,
compared with the totality of the patients recorded in the
registry, ACPA-negative ASS patients included in this study
had higher frequency of polyarthralgia (85% vs 63%, P< 0.05)
and polyarthritis (41% vs 20%, P< 0.05).25 Thus, our study
may actually underestimate the prognostic significance of
ACPA statute for joint disease in ASS patients.
In summary, the present series demonstrates that ASS can
overlap with RA. The recognition of this setting among patients
diagnosed with ASS, but also in patients diagnosed with RA,
has important implications for both prognosis and management.
ACPA-positive ASS patients display extrarheumatic manifes-
tations similar to ACPA-negative ASS patients and are at high
risk of developing erosive arthritis refractory to DMARDs.
Conversely, to anti-TNF drugs, anti-CD20 mAb may be effec-
tive and well tolerated in these patients, without exacerbating
extra-articular involvements.
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